semaglutide bimagrumab Once-weekly 2.4 mg led to significant decreases in body weight and fat mass over 12 months while preserving lean mass and improved muscle function in adults with obesity. Weight and fat Combination bimagrumab plus semaglutide confers

These findings have significant implications for developing supportive care protocols that reduce long-term chemotherapy side effects and improve quality of life for cancer survivors

At present, no pharmacological therapies are approved for MASH, and current management approaches are focused on lifestyle modification, like a low-calorie diet, physical activityboth aerobic and resistance trainingand cognitive behavioural therapy [6], to obtain weight loss and, at the same time, improve other related conditions, namely, blood pressure, triglycerides levels and insulin resistance

The pros and cons of each available GLP-1 RA were discussed with JM to determine which agent would best meet his goals

Oral semaglutide 25 mg (Wegovy pill) , FDA-approved December 22, 2025, is the first oral GLP-1 approved for chronic weight management

Wegovy (semaglutide) Wegovy was approved by the FDA for chronic weight management in adults and adolescents with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol